Two translational science threads drew attention for their focus on tissue injury mechanisms. In experimental cardiac injury biology, researchers highlighted how MARCH2 helps guard cardiac cells from doxorubicin toxicity by stabilizing NR1H2 and clearing cells—work reported in Nature Communications. On the regenerative side, epigenetic control of liver recovery was tied to Suv39h1 and HMGB2, where Suv39h1 appears to function as a regulatory brake on liver cell proliferation after injury. The study points to histone methylation pathways as leverage points for improving regrowth and tissue recovery following damage. Together, the reports emphasize mechanistic targets—cardiomyopathy prevention and liver regeneration regulation—rather than broad symptomatic approaches, aligning with how preclinical findings increasingly feed both therapeutic target selection and early translational plans.